CD8A and ganglioneuroma: After confirmation of deletion of CD8 + T cells by anti-CD8α antibody being continued for 1 to 2 weeks (Supplementary Fig. S6a–c), when mice were injected with anti-CD8α antibody at initial treatment, the significant anti-tumor effect observed in mice treated with GN + OBP-702 disappeared (Fig. 5c).